Trial
NCT00702221
Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
BTG International Inc.
Collaborators
Encorium
Condition
Hypertension
Intervention
Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant
Why stopped
Dose limiting adverse effects
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-29